Drug Trial Radar · NCT07845266
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Apr 16, 2024
Primary completion
Apr 9, 2025
Study completion Dec 4, 2025
Sponsor
- Lead sponsor
- Beijing Gene Key Life Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase Ia study evaluated the safety and tolerability of a single escalating dose via intravenous infusion of the autologous invariant natural killer T cells (iNKT-cell) product GKL-006 in combination with transarterial chemoembolisation (TACE) in participants with unresectable hepatocellular carcinoma (uHCC). The study aimed to characterise dose-limiting toxicities (DLT), determine the maximum tolerated dose (MTD), and assess pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumour activity.
Conditions
- Hepatocellular Carcinoma (HCC)
- Unresectable Hepatocellular Carcinoma
Interventions
GKL-006 InjectionBiological
Autologous iNKT cells collected and reinfused after in vitro cultivation.
transarterial chemoembolizationDrug
A standard locoregional therapy for hepatocellular carcinoma.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose(MTD)of GKL-006Time frame: From the GKL-006 infusion until 28 days.
- Incidence of Dose-Limiting Toxicities (DLTs)Time frame: From GKL-006 infusion through Day 28
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Ditan Hospital Chaoyang Campus
Beijing, Beijing Municipality, China
Beijing Youan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.